Literature DB >> 32016488

CX3CR1 positively regulates BCR signaling coupled with cell metabolism via negatively controlling actin remodeling.

Na Li1, Panpan Jiang2, Anwei Chen3, Xi Luo4, Yukai Jing2, Lu Yang2, Danqing Kang2, Qiuyue Chen1, Ju Liu2, Jiang Chang2, Julia Jellusova5, Heather Miller6, Lisa Westerberg7, Cong-Yi Wang4, Quan Gong8, Chaohong Liu9.   

Abstract

As an important chemokine receptor, the role of CX3CR1 has been studied extensively on the migration of lymphocytes including T and B cells. Although CX3CR1+ B cells have immune suppressor properties, little is known about its role on the regulation of BCR signaling and B cell differentiation as well as the underlying molecular mechanism. We have used CX3CR1 KO mice to study the effect of CX3CR1 deficiency on BCR signaling and B cell differentiation. Interestingly, we found that proximal BCR signaling, such as the activation of CD19, BTK and SHIP was reduced in CX3CR1 KO B cells upon antigenic stimulation. However, the activation of mTORC signaling was enhanced. Mechanistically, we found that the reduced BCR signaling in CX3CR1 KO B cells was due to reduced BCR clustering, which is caused by the enhanced actin accumulation by the plasma membrane via increased activation of WASP. This caused an increased differentiation of MZ B cells in CX3CR1 KO mice and an enhanced generation of plasma cells (PC) and antibodies. Our study shows that CX3CR1 regulates BCR signaling via actin remodeling and affects B cell differentiation and the humoral immune response.

Entities:  

Keywords:  B cell; BCR signaling; CX3CR1; Metabolism

Mesh:

Substances:

Year:  2020        PMID: 32016488     DOI: 10.1007/s00018-019-03416-7

Source DB:  PubMed          Journal:  Cell Mol Life Sci        ISSN: 1420-682X            Impact factor:   9.261


  2 in total

Review 1.  Ibrutinib in the Treatment of Solid Tumors: Current State of Knowledge and Future Directions.

Authors:  Katarzyna Szklener; Adam Michalski; Klaudia Żak; Michał Piwoński; Sławomir Mańdziuk
Journal:  Cells       Date:  2022-04-14       Impact factor: 7.666

2.  CCL2 regulation of MST1-mTOR-STAT1 signaling axis controls BCR signaling and B-cell differentiation.

Authors:  Lu Yang; Na Li; Di Yang; Anwei Chen; Jianlong Tang; Yukai Jing; Danqing Kang; Panpan Jiang; Xin Dai; Li Luo; Qiuyue Chen; Jiang Chang; Ju Liu; Heng Gu; Yanmei Huang; Qianglin Chen; Zhenzhen Li; Yingzi Zhu; Heather Miller; Yan Chen; Liru Qiu; Heng Mei; Yu Hu; Quan Gong; Chaohong Liu
Journal:  Cell Death Differ       Date:  2021-04-20       Impact factor: 12.067

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.